临床输血与检验2017，Vol.19Issue(3)：248-251,4.DOI:10.3969/j.issn.1671-2587.2017.03.012
深圳地区103例非小细胞肺癌患者EGFR基因突变分析
Analysis of EGFR Gene Mutation in 103 Patients with Non-small Cell Lung Cancer in Shenzhen
摘要
Abstract
ObjectiveTo understand non-small cell lung cancer(NSCLC)epidermal growth factor receptor (EGFR) mutations in Shenzhen,and to provide a basis for target therapy of NSCLC patients.Methods collected from March 2013 to November 2015 in shenzhen area three level 3 district hospital,One hundred and three cases of NSCLC cancer tissues were collected in 3 hospitals from 2013 to 2015,and DNA was extracted followed by detections of EGFR gene mutation in exon 18,19,20 and 2l using mutations specific amplification system (ARMS) amplification.Results All of 103 cases of NSCLC showed an EGFR gene mutation rate of 38.8% (40/103),among them 18,19,20 and 21 exon mutations rates were 2.5%(1/40),35.0%(14/40),5.0%(2/40),and 57.5%(23/40),respectively. EGFR mutation rate was 48.7% (37/76)in patients with adenocarcinoma,higher than 11.1%(3/27)in the patients with non-adenocarcinoma.(χ2=25.617,P<0.01). EGFR mutation rate in NSCLC patients of nonsmookers was 56.1% (32/57), significantly higher than the smooker patients( 17.4%,8/46) (χ2=20.195,P<0.01). The mutation rate in female patients was 52.4%(22/42),higher than that of the male (29.5%,18/61)(χ2=5.127,P<0.05). The patients below 56 years exhibited an EGFR mutation rate of 39.5% (17/43),compared to those over 56 years (38.3%,23/60) (χ2=0.618,P>0.618).Conclusion EGFR mutations in NSCLC patients are mainly composed of exon 21,followed by exon19. Adenocarcinoma,femal,and nonsmoker patients seem to be the risk factors of EGFR gene mutation.关键词
非小细胞肺癌/表皮生长因子受体/基因突变Key words
Non-small cell lung cancer/Epidermal growth factor receptor/Gene mutations分类
医药卫生引用本文复制引用
王礼法,刘爱胜,余树林,施俊柱,程文德,刘小君..深圳地区103例非小细胞肺癌患者EGFR基因突变分析[J].临床输血与检验,2017,19(3):248-251,4.基金项目
本课题受广东省深圳市龙华新区科技创新项目(No.2015-0924A103085)资助 （No.2015-0924A103085）
